ScreenerHero

GDTC CytoMed Therapeutics Limited

NAS · US · Healthcare · Biotechnology · w2.cytomed.sg
0.9800USD+5.40%Mkt Cap: 11.70M $P/E: —

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap11.70M USD
Enterprise Value10.52M USD
Revenue (TTM)789.04K USD
Gross Profit256.39K USD
Net Income (TTM)-3.98M USD
Revenue/Share0.07 USD
Last Price0.9800 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees42
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.20
PEG—
EV/EBITDA-2.96
EV/Revenue13.33
P/S14.06
P/B2.83
EPS (TTM)-0.22
EPS (Forward)-0.15
52W Range
0.680010% of range3.680
52W High3.680 USD
52W Low0.6800 USD
Profitability
Gross Margin79.04%
Oper. Margin-476.09%
EBITDA Margin0.00%
Profit Margin-1227.07%
ROE-60.82%
ROA-49.85%
Growth
Revenue Growth-15.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.70M USD
CapEx (TTM)703.13K USD
FCF Margin-300.02%
FCF Yield-20.24%
Net Debt-1.00M USD
Net Debt/EBITDA0.28
Balance Sheet
Debt/Equity0.07
Current Ratio2.64
Quick Ratio1.51
Book Value/Sh0.33 USD
Cash/Share0.12 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.160 USD
Upside (mean)+324.5%
Target Range4.160 USD – 4.160 USD
# Analysts1
Ownership
Shares Out.11.93M
Float3.60M
Insiders69.87%
Institutions0.14%
Short Interest
Short Ratio0.2d
Short % Float0.10%
Short % Out.0.03%
Shares Short3.62K
Short (prev mo.)4.21K
Technical
SMA 500.8968 (+9.3%)
SMA 2001.025 (-4.4%)
Beta0.07
S&P 52W Chg16.45%
Avg Vol (30d)18.70K
Avg Vol (10d)20.80K
Technical Indicators
RSI (14)55.4
MACD0.0131
MACD Signal0.0037
MACD Hist.+0.0095
BB Upper1.030 USD
BB Middle0.8972 USD
BB Lower0.7645 USD
BB Width29.58%
ATR (14)0.1168 USD
Vol Ratio (20d)0.84x